Special drug use survey of Tremfya for palmoplantar pustulosis

Special drug use survey of Tremfya for palmoplantar pustulosis - TRM2L

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036102

Enrollment

200

Registered

2019-03-06

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

palmoplantar pustulosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with palmoplantar pustulosis who initiate Tremfya in accordance with the indication in package insert.

Exclusion criteria

Exclusion criteria: Patients with a history of the use of ustekinumab (active ingredient of this product)

Design outcomes

Primary

Measure	Time frame
Variables related to safety a.Data on adverse reactions/infection b.Data on adverse reactions of primary survey items c.Factors possibly affecting the safety d.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder) e.Data on adverse reactions of malignancy after long term of administration Variables related to efficacy a.efficacy (PPPASI) b.Factors possibly affecting the efficacy c.Investigation of the efficacy in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder)	—

Measure

Time frame

Variables related to safety a.Data on adverse reactions/infection b.Data on adverse reactions of primary survey items c.Factors possibly affecting the safety d.Investigation of the safety in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder) e.Data on adverse reactions of malignancy after long term of administration Variables related to efficacy a.efficacy (PPPASI) b.Factors possibly affecting the efficacy c.Investigation of the efficacy in specific patient populations (the elderly, pregnant/nursing women, patients with renal impairment, patients with hepatic function disorder)

—

Countries

Japan

Contacts

Public ContactKeiko Imai

Janssen Pharmaceutical K.K. Medical Affiars Delivery Unit

kimai4@ITS.JNJ.com+818023618773

Outcome results